- Home
- EVOK vs RDHL Comparison
EVOK vs RDHL Comparison
Compare EVOK & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVOK | RDHL |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.4M | 3.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | EVOK | RDHL |
|---|---|---|
| Price | $11.00 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 30.8K | ★ 75.2K |
| Earning Date | 11-13-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,424,652.00 | $9,550,000.00 |
| Revenue This Year | $58.96 | $381.91 |
| Revenue Next Year | $57.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 67.40 | ★ 157.62 |
| 52 Week Low | $1.94 | $1.01 |
| 52 Week High | $11.00 | $7.30 |
Technical Indicators
Market Signals| Indicator | EVOK | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 85.30 | 48.19 |
| Support Level | $10.66 | $1.15 |
| Resistance Level | $10.99 | $1.24 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.18 | 0.01 |
| Stochastic Oscillator | 100.00 | 38.64 |
Price Performance
Historical ComparisonAbout EVOK Evoke Pharma Inc.
Evoke Pharma Inc is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal, or GI, disorders, and diseases. The company's product Gimoti is an investigational metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti is a novel nasal spray formulation of metoclopramide designed to provide systemic delivery of the molecule through the nasal mucosa.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.